Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
30 Cards in this Set
- Front
- Back
- 3rd side (hint)
Lispro
|
Rapid Acting Insulin
|
|
|
Aspart
|
Rapid acting insulin
|
|
|
regular insulin
|
rapid acting insulin
|
|
|
NPH
|
intermediate acting insulin
|
|
|
glargine
|
intermediate acting insulin
|
|
|
detemir
|
intermediate acting insulin
|
|
|
Insulin (Action...)
|
Liver: increase glucose stored as glycogen
muscle: increase glycogen and protein synthesis, K+ uptake Fat: aids triglyceride storage |
Use: DMI, DMII, gestational diabetes, life threatening hyperkalemia, stress induced hyperglycemia
Toxicities: hyopglycemia, hypersensitivity reaction (very rare) |
|
tolbutamide
|
first generation sulfonylurea
|
|
|
chloropropamide
|
first generation sulfonylurea
|
|
|
glyburide
|
second generation sulfonylurea
|
|
|
glimepiride
|
second generation sulfonylurea
|
|
|
glipizide
|
second generation sulfonylurea
|
|
|
sulfonylurea (Action...)
|
close K+ channel in beta cell membrane so cell depolarizes causing insulin release by allowing calcium to enter
|
Use: stimulate release of endogenous insulin in type II DM
Toxicities: first gen- disulfram like effects second gen- hypoglycemia |
|
metformin
|
increase glycolysis and peripheral glucose uptake, decrease gluconeogenesis
|
Use: can be given to type I or type II
Toxicity: lactic acidosis, contraindicated in renal failure |
|
pioglitazone
|
glitazone/ thiazolidinediones
|
|
|
rosiglitazone
|
glitazone/ thiazolidinediones
|
|
|
glitazone/ thiazolidinediones
|
increase insulin sensitivity in peripheral tissue by binding to PPAR gamma nucear transcription regulator
|
Use: monotherapy or in combination
Toxicity: weight gain, edema, hepatotoxicity, cardiotoxicity |
|
acarbose
|
alpha glucosidae inhibitor
|
|
|
alpha glucosidase inhibitor
|
inhibit bursh border alpha glucosidases so sugar hydrolysis and glucose absorption are delayed. leads to a decrease in post-prandial hyperglycemia
|
Use: monotherapy in DM II or combination
Toxicities: GI disturbances |
|
exantide
|
GLP-1 analogue that increases insulin and decreases glucagon
|
Use: type II DM
toxicity: nausea, vomiting, pancreatitis |
|
Propylthiourcail (PTU)
|
inhibitors organification of iodide and coupling of thyroid hornome synthesis, decreases peripheral conversion of T4 to T3
|
Use: hyperthyroidism
Toxicity: skin rash, agranulocytosis (rarely) aplastic anemia, |
|
methimazole
|
inhibitors organification of iodide and coupling of thyroid hornome synthesis
|
Use: hyperthyroidism
Toxicity: skin rash, agranulocytosis (rarely) aplastic anemia, possible teratogen |
|
Levothyroxine
|
thyroxine replacement
|
Use: hypothyroidism, myxedema
Toxicity: tachycardia, heat intolerance, tremors, arrhythmias |
|
triiodothyronine
|
thyroxine replacement
|
Use: hypothyroidism, myxedema
Toxicity: tachycardia, heat intolerance, tremors, arrhythmias |
|
GH
|
GH deficiency, Turner's syndrome(increase height), Prader-Willi syndrome (decrease body fat, increase muscle ration)
|
|
|
Somatostatin
|
acromegaly, carcinoid, gastrinoma, glucagonoma
|
|
|
Demeclocycline
|
ADH antagonist (a tetracycline)
|
'Use: SIADH
Toxicity: nephrogenic DI, photosensitivity, abnormalities of bone and teeth |
|
Terlipressin
|
Receptor V1 agonist
|
Esophageal Varices
|
|
Desmopressin
|
Recptor V2 agonist
|
1.Treat Central diabetes insipidus
2.increase VIII and vWF |
|
glucocorticoids
|
decrease the production of leukotrienes and prostaglandins by inhibiting PLA2 and expression of cox 2
|
Use: Addison's, inflammation, immune suppression, asthma
Toxicity: iatrogenic Cushing's; adrenal insufficiency when drug is stopped |